PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges - 30/11/19
pages | 14 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | A review specifically summarising PD-1 disrupted CAR T cells as cancer therapeutics. |
• | Antitumor activity of CAR T cells can be enhanced significantly by PD-1 disruption. |
• | This new combination strategy could be the new hope for solid tumor treatment. |
• | Increasing number of clinical trials on these CAR T cells have been commenced. |
• | Future prospects & challenges of this new combination strategy are discussed. |
Abstract |
Unprecedented efficacy of chimeric antigen receptor (CAR) T cell therapy in the treatment of hematologic malignancies brings new hope for patients with many cancer types including solid tumors. However, the challenges for CAR-T cell therapy in eradicating solid tumors are immense. To overcome these seemingly intractable hurdles, more “powerful” CAR-T cells with enhanced antitumor efficacy are required. Emerging data support that the anti-tumor activity of CAR-T cells can be enhanced significantly without evident toxicity through simultaneous PD-1 disruption by genome editing. This review focuses on the current progress of PD-1 gene disrupted CAR-T cells in cancer therapy. Here we discuss key rationales for this new combination strategy and summarize the available pre-clinical studies. An update is provided on human clinical studies and available registered cancer clinical trials using CAR-T cells with PD-1 disruption. Future prospects and challenges are also discussed.
Le texte complet de cet article est disponible en PDF.Keywords : Immunotherapy, Chimeric antigen receptor T cells, CAR-T cells, PD-1, Gene editing
Plan
Vol 121
Article 109625- janvier 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?